Product Program year 2025 Source: CMS Open Payments

Evrysdi

Drug Neurology

NDC 50242-175-07

Open in the dashboard

General payments

$1,594,773

3,632 payments

Research payments

$14,752,248

720 payments

Through program year 2025, $1,594,773 in general payments and $14,752,248 in research payments were reported against Evrysdi (Neurology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

12 rows
Year Kind Amount Payments
2025 General $268,538 634
2025 Research $1,141,521 227
2024 General $333,419 807
2024 Research $1,210,338 152
2023 General $382,429 1,049
2023 Research $3,675,053 83
2022 General $275,777 651
2022 Research $4,003,214 102
2021 General $215,232 349
2021 Research $4,166,955 100
2020 General $119,379 142
2020 Research $555,167 56

Breakdown

Who paid General payments · program years 2020–2025
  1. Genentech USA, Inc. $1,281,432 3,028 payments
  2. F. Hoffmann-La Roche AG $139,775 76 payments
  3. Genentech, Inc. $126,065 494 payments
  4. Roche Products Limited $36,641 29 payments
  5. Hoffmann-La Roche Limited $10,860 5 payments
Top recipients General payments · program year 2025
  1. Shade Moody Neurology with Special Qualifications in Child Neurology · Houston, TX $30,157 11% · 60 payments
  2. Shafeeq Ladha Neuromuscular Medicine · Phoenix, AZ $28,020 10% · 23 payments
  3. Perry Shieh Neurology · Los Angeles, CA $25,775 10% · 34 payments
  4. Omer Abdul Hamid Neurology with Special Qualifications in Child Neurology · Orlando, FL $19,968 7% · 13 payments
  5. Manisha Korb Neuromuscular Medicine · West Palm Beach, FL $17,953 7% · 12 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Neurology with Special Qualifications in Child Neurology Psychiatry & Neurology $90,325 38% · 75 practitioners
  2. Neuromuscular Medicine Psychiatry & Neurology $59,332 25% · 12 practitioners
  3. Neurology Psychiatry & Neurology $56,797 24% · 63 practitioners
  4. Emergency Medical Services Emergency Medicine $11,400 5% · 1 practitioner
  5. Nurse Practitioner, Pediatrics Nurse Practitioner $7,106 3% · 14 practitioners

The top 5 of 35 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. California $69,795 26% · 24 recipients
  2. Texas $31,852 12% · 42 recipients
  3. Minnesota $28,096 10% · 3 recipients
  4. Florida $20,959 8% · 30 recipients
  5. Illinois $15,596 6% · 7 recipients

The top 5 of 39 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

4,965

Prescriptions dispensed, refills included

Drug cost

$136,162,768

Paid at the pharmacy, in all

Prescribers

188

With 11 or more claims of it

Medicare Part D drugs matched to Evrysdi, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Evrysdi Risdiplam Same name 188 4,965 $136,162,768

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Bakri Elsheikh Neurology OH 115 $3,038,980 None on record
Mario Saporta Neurology FL 108 $3,193,814 None on record
Stacy Dixon Neurology CO 97 $2,672,325 None on record
Peter Karachunski Neurology MN 90 $2,566,169 None on record
Nanette Joyce Physical Medicine and Rehabilitation CA 90 $2,395,517 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
3,632 general · 720 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record